![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 1217-1227, March 2003
Neurocrine Biosciences Inc., San Diego, California
The molecular basis of ligand recognition by the melanocortin 4 receptor (MC4R) has not been fully defined. In this study, we
investigated the molecular determinants of MC4R ligand binding, employing a large array of ligands, using three approaches. First, molecular modeling of the receptor was used to identify Phe284, in
transmembrane (TM) 7, as a potential site of ligand interaction. Mutation of Phe284 to alanine reduced binding affinity and potency of
peptides containing L-Phe by up to 71-fold but did not
appreciably affect binding of linear peptides containing
D-Phe, consistent with a hydrophobic interaction between
the Phe7 of
-melanocyte-stimulating hormone and Phe284.
Second, we examined the effect of a naturally occurring mutation in TM3
(I137T) that is linked to obesity. This mutation decreased affinity and
potency of cyclic, rigid peptides but not more flexible peptides,
consistent with an indirect effect of the mutation on the tertiary
structure of the receptor. Third, we examined the residues that support
ligand selectivity for the MC4R over the MC3R. Mutation of Ile125 (TM3)
of the MC4R to the equivalent residue of the MC3R (phenylalanine)
selectively decreased affinity and potency of MC4R-selective ligands.
This effect was mirrored by the reciprocal MC3R mutation F157I. The
magnitude of this effect indicates that this locus is not of major
importance. However, it is considered that an isoleucine/phenylalanine
mutation may affect the orientation of Asp122, which has been
identified as a major determinant of ligand binding affinity. Thus,
this study provides further characterization of the MC4R binding pocket.
This article has been cited by other articles:
![]() |
C. J. Russo, E. Melista, J. Cui, A. L. DeStefano, G. L. Bakris, A. J. Manolis, H. Gavras, and C. T. Baldwin Association of NEDD4L Ubiquitin Ligase With Essential Hypertension Hypertension, September 1, 2005; 46(3): 488 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Markison, A. C. Foster, C. Chen, G. B. Brookhart, A. Hesse, S. R. J. Hoare, B. A. Fleck, B. T. Brown, and D. L. Marks The Regulation of Feeding and Metabolic Rate and the Prevention of Murine Cancer Cachexia with a Small-Molecule Melanocortin-4 Receptor Antagonist Endocrinology, June 1, 2005; 146(6): 2766 - 2773. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Nickolls, B. Fleck, S. R. J. Hoare, and R. A. Maki Functional Selectivity of Melanocortin 4 Receptor Peptide and Nonpeptide Agonists: Evidence for Ligand-Specific Conformational States J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1281 - 1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lapinsh, S. Veiksina, S. Uhlen, R. Petrovska, I. Mutule, F. Mutulis, S. Yahorava, P. Prusis, and J. E. S. Wikberg Proteochemometric Mapping of the Interaction of Organic Compounds with Melanocortin Receptor Subtypes Mol. Pharmacol., January 1, 2005; 67(1): 50 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Valli-Jaakola, M. Lipsanen-Nyman, L. Oksanen, A. N. Hollenberg, K. Kontula, C. Bjorbaek, and C. Schalin-Jantti Identification and Characterization of Melanocortin-4 Receptor Gene Mutations in Morbidly Obese Finnish Children and Adults J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 940 - 945. [Abstract] [Full Text] [PDF] |
||||